Literature DB >> 19017985

Interaction between RANTES promoter variant and CCR5Delta32 favors recovery from hepatitis B.

Chloe L Thio1, Jacquie Astemborski, Rasmi Thomas, Timothy Mosbruger, Mallory D Witt, James J Goedert, Keith Hoots, Cherie Winkler, David L Thomas, Mary Carrington.   

Abstract

Recovery from acute hepatitis B virus (HBV) infection occurs in 95% of adult-acquired infections. A 32-bp deletion in CCR5 (CCR5Delta32), which encodes for a nonfunctional receptor, increases the likelihood of recovery. Using 181 subjects with persistent HBV infection and 316 who had recovered, we tested the hypothesis that an epistatic interaction between functional polymorphisms in RANTES (a CCR5 ligand) and CCR5 impacts recovery. Specific models designed to assess individual contributions of compound genotypes demonstrated that the only combination associated with recovery from an HBV infection was RANTES -403A with CCR5Delta32 (odds ratio 0.36, p = 0.02). Because the phenotypic consequence of -403A is reported to be higher levels of RANTES, we propose a model in which excess RANTES in combination with low CCR5 favors recovery from an HBV infection, which will require validation through functional testing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19017985      PMCID: PMC2650505          DOI: 10.4049/jimmunol.181.11.7944

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  A new statistical method for haplotype reconstruction from population data.

Authors:  M Stephens; N J Smith; P Donnelly
Journal:  Am J Hum Genet       Date:  2001-03-09       Impact factor: 11.025

2.  Polymorphism in RANTES chemokine promoter affects extent of sarcoidosis in a Japanese population.

Authors:  T Takada; E Suzuki; T Ishida; H Moriyama; H Ooi; T Hasegawa; H Tsukuda; F Gejyo
Journal:  Tissue Antigens       Date:  2001-11

3.  The effect of RANTES chemokine genetic variants on early HIV-1 plasma RNA among African American injection drug users.

Authors:  Priya Duggal; Cheryl A Winkler; Ping An; Xiao-Fang Yu; Homayoon Farzadegan; Stephen J O'Brien; Terri H Beaty; David Vlahov
Journal:  J Acquir Immune Defic Syndr       Date:  2005-04-15       Impact factor: 3.731

4.  Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES.

Authors:  R G Nickel; V Casolaro; U Wahn; K Beyer; K C Barnes; B S Plunkett; L R Freidhoff; C Sengler; J R Plitt; R P Schleimer; L Caraballo; R P Naidu; P N Levett; T H Beaty; S K Huang
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

5.  Association of genetic variations in CCR5 and its ligand, RANTES with clearance of hepatitis B virus in Korea.

Authors:  Sang Hoon Ahn; Do Young Kim; Hye Young Chang; Sun Pyo Hong; Jeon-Soo Shin; Yu Seun Kim; Hyejin Kim; Ja Kyung Kim; Yong Han Paik; Kwan Sik Lee; Chae Yoon Chon; Young Myoung Moon; Kwang-Hyub Han
Journal:  J Med Virol       Date:  2006-12       Impact factor: 2.327

6.  Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus.

Authors:  T C Dawson; M A Beck; W A Kuziel; F Henderson; N Maeda
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

7.  Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence.

Authors:  Chloe L Thio; Jacquie Astemborski; Arman Bashirova; Timothy Mosbruger; Spencer Greer; Mallory D Witt; James J Goedert; Margaret Hilgartner; Audrey Majeske; Stephen J O'Brien; David L Thomas; Mary Carrington
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  Abnormal immune response of CCR5-deficient mice to ocular infection with herpes simplex virus type 1.

Authors:  Daniel J J Carr; John Ash; Thomas E Lane; William A Kuziel
Journal:  J Gen Virol       Date:  2006-03       Impact factor: 3.891

9.  CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis.

Authors:  Maureen N Ajuebor; Zenebech Wondimu; Cory M Hogaboam; Tai Le; Amanda E I Proudfoot; Mark G Swain
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

10.  RANTES, MCP-1, CCR2, CCR5, CXCR1 and CXCR4 gene polymorphisms are not associated with the outcome of hepatitis B virus infection: results from a large scale single ethnic population.

Authors:  Jae Youn Cheong; Sung Won Cho; Jeong Young Choi; Jung A Lee; Min Ho Kim; Jong Eun Lee; Ki Baik Hahm; Jin Hong Kim
Journal:  J Korean Med Sci       Date:  2007-06       Impact factor: 2.153

View more
  8 in total

1.  Chemokine (CCR) and fractalkine (CX3CR) receptors and end stage renal disease.

Authors:  Minal Borkar; Gaurav Tripathi; Raj Kumar Sharma; Satya Narayan Sankhwar; Suraksha Agrawal
Journal:  Inflamm Res       Date:  2010-12-04       Impact factor: 4.575

2.  A novel variant marking HLA-DP expression levels predicts recovery from hepatitis B virus infection.

Authors:  Rasmi Thomas; Chloe L Thio; Richard Apps; Ying Qi; Xiaojiang Gao; Darlene Marti; Judy L Stein; Kelly A Soderberg; M Anthony Moody; James J Goedert; Gregory D Kirk; W Keith Hoots; Steven Wolinsky; Mary Carrington
Journal:  J Virol       Date:  2012-04-11       Impact factor: 5.103

Review 3.  Clinical use of CCR5 inhibitors in HIV and beyond.

Authors:  Bruce L Gilliam; David J Riedel; Robert R Redfield
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

4.  CCR5 Polymorphism as a Protective Factor for Hepatocellular Carcinoma in Hepatitis B Virus-Infected Iranian Patients

Authors:  Reza Abdolmohammadi; Saleh Shahbazi Azar; Ayyoob Khosravi; Majid Shahbazi
Journal:  Asian Pac J Cancer Prev       Date:  2016-10-01

Review 5.  Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases.

Authors:  Joel Henrique Ellwanger; Bruna Kulmann-Leal; Valéria de Lima Kaminski; Andressa Gonçalves Rodrigues; Marcelo Alves de Souza Bragatte; José Artur Bogo Chies
Journal:  Virus Res       Date:  2020-05-30       Impact factor: 3.303

6.  Network pharmacology-based study on the mechanism of Yiganling capsule in hepatitis B treatment.

Authors:  Chao Lu; Wanjin Fu; Renpeng Zhou; Wei Hu
Journal:  BMC Complement Med Ther       Date:  2020-02-05

7.  CCR5 on the NK Cells and its Ligand (RANTES) Expressions are Disrupted in South-Eastern Iranian Patients With Chronic Hepatitis B Infection.

Authors:  Vahid Mirzaee; Jahanbano Shahriari; Masomeh Hajghani
Journal:  Iran Red Crescent Med J       Date:  2014-04-05       Impact factor: 0.611

Review 8.  Targeting CCL5 in inflammation.

Authors:  Rafael Elias Marques; Rodrigo Guabiraba; Remo Castro Russo; Mauro Martins Teixeira
Journal:  Expert Opin Ther Targets       Date:  2013-10-03       Impact factor: 6.902

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.